http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6281248-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
| filingDate | 2000-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76bbd263501405ada8bce8ef146e512b |
| publicationDate | 2001-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6281248-B1 |
| titleOfInvention | Composition for treating asthma |
| abstract | A method of treating asthma that includes the step of controlling the asthma by ingesting a composition which includes a selective serotonin reuptake inhibitor that is sertraline hydrochloride. Chronic administration of the sertraline thereof downregulates brain norepinephrine receptors. The increased output of the brain norepinephrine receptors increases the dilation of the bronchi. Sertraline has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors. Antagonism of such receptors has been hypothesized to be associated with various adverse anticholinergic, sedative, and cardiovascular effects. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004220153-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1553955-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1553955-A2 |
| priorityDate | 2000-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 122.